Contusugene ladenovec - Gendux/Introgen

Drug Profile

Contusugene ladenovec - Gendux/Introgen

Alternative Names: Ad-p53; Ad5CMV-p53; Adenoviral p53; ADVEXIN; Contusugene ladenovec Gendux; INGN 201; RPR/INGN 201

Latest Information Update: 05 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gendux; Introgen Therapeutics
  • Developer Gendux; Introgen Therapeutics; National Cancer Institute (USA)
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer; Li-Fraumeni syndrome

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Bronchiolo-alveolar adenocarcinoma; Glioblastoma; Head and neck cancer; Li-Fraumeni syndrome; Non-small cell lung cancer; Oesophageal cancer; Orofacial cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 05 Nov 2009 Discontinued - Clinical-Phase-Unknown for Li-Fraumeni syndrome in USA (IV)
  • 05 Nov 2009 Discontinued - Phase-I for Bladder cancer in USA (Intratumoural)
  • 05 Nov 2009 Discontinued - Phase-I for Bronchiolo alveolar adenocarcinoma in USA (Intratracheal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top